Tag: Mirvetuximab soravtansine
ImmunoGen and FDA Discuss Ongoing Development for Mirvetuximab Soravtansine
The United States Food and Drug Administration (FDA) has recommended that ImmunoGen conducts a new Phase III randomized trial to evaluate the safety and...
FORWARD I Phase III Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian...
The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of...
Amid Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes...
A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company's...
Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...
Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
ImmunoGen and Merck Evaluate Mirvetuximab Soravtansine in Combination with Pembrolizumab in...
ImmunoGen and Merck, known as MSD outside the United States and Canada, have entered into a clinical research collaboration for the assessment of ImmunoGen's...
Treatment Response to Mirvetuximab Soravtansine Found to be Substantially Greater in...
Findings with mirvetuximab soravtansine (also known as IMGN853 and M9346A-sulfo-SPDB-DM4), a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate being developed by ImmunoGen, a clinical-stage...
ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...
